What is the study drug and how does it work?
The study drug (called inebilizumab) is designed to reduce the immune system's ability to attack your muscles, which may improve communication between your nerves and muscles. What we learn from MINT may help us learn if inebilizumab can help people with myasthenia gravis (MG).
What is an investigational drug or medicine?
Investigational means that a drug or therapy has not been approved to treat MG by authorities that regulate new medicines, such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
Have other people used the study drug?
Yes. MINT is a Phase 3 study, which means inebilizumab has been studied in other people with other autoimmune conditions. Inebilizumab has been approved in the United States and Japan to treat a different autoimmune disease (neuromyelitis optica spectrum disorder in adults who are positive for anti-aquaporin-4 antibodies).